| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA977: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over |
|
Medicine details |
|
| Medicine name | dabrafenib (Finlee®) and trametinib (Spexotras®) |
| Formulation | dabrafenib -10 mg dispersible tablets; 4.7 mg bottle of 0.05 mg per ml powder for oral solution: trametinib - 0.05 mg/ml powder for oral solution |
| Reference number | 4995 |
| Indication | Dabrafenib in combination with trametinib for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. Dabrafenib in combination with trametinib for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment. |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/04/2024 |
| NICE guidance | |
| Commercial arrangement | PAS |